Advrs effect of immune chkpt inhibtr/immunostim drugs, init

This code signifies an initial adverse reaction to medications that either stimulate the immune system (immunostimulants) or block immune checkpoints, which are commonly used in cancer therapy. It indicates that the patient is experiencing the first manifestation of a harmful or unintended side effect from these specific drug classes.

Use this code when a patient presents with a newly identified adverse event directly attributable to immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab) or other immunostimulant drugs. This applies to the initial assessment and treatment of conditions like immune-related pneumonitis, colitis, or endocrinopathies following the administration of these agents.

• Always sequence this code first when it represents the primary reason for the encounter due to the adverse effect.
• Assign additional codes to specify the exact nature of the adverse effect (e.g., specific organ involvement like colitis, hepatitis).
• Do not use this code for poisoning, underdosing, or allergic reactions not classified as adverse effects.